Adverse Event Management Practices in SCLC
Eric Singhi, MD, joins the Oncology Brothers to discuss adverse event management practices for patients with small cell lung cancer.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
!["Early [concurrent] CRT provides a significant survival benefit, while late [concurrent] CRT is an acceptable option," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Ffc2a0cb8c6d287fa539f7d61aad18a8752d347dc-1200x882.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"Early [concurrent] CRT provides a significant survival benefit, while late [concurrent] CRT is an acceptable option,\" according to the study authors.")
!["This [network meta-analysis] demonstrated for the first time that [anlotinib/benmelstobart plus chemotherapy] is the most efficacious regimen for extending survival in ES-SCLC, highlighting its potential as a preferred first-line treatment option for this patient population," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6934d676a539495d8b2109e4b3762700aa723bf3-1200x873.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"This [network meta-analysis] demonstrated for the first time that [anlotinib/benmelstobart plus chemotherapy] is the most efficacious regimen for extending survival in ES-SCLC, highlighting its potential as a preferred first-line treatment option for this patient population,\" according to the study authors.")
